| The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes D Altshuler, JN Hirschhorn, M Klannemark, CM Lindgren, MC Vohl, ... Nature genetics 26 (1), 76-80, 2000 | 2428 | 2000 |
| Simvastatin with or without ezetimibe in familial hypercholesterolemia JJP Kastelein, F Akdim, ESG Stroes, AH Zwinderman, ML Bots, ... New England Journal of Medicine 358 (14), 1431-1443, 2008 | 1837 | 2008 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1773 | 2018 |
| Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? I Lemieux, A Pascot, C Couillard, B Lamarche, A Tchernof, N Almeras, ... Circulation 102 (2), 179-184, 2000 | 1511 | 2000 |
| Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised … FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, ... The Lancet 375 (9719), 998-1006, 2010 | 1133 | 2010 |
| Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease JD Rioux, MJ Daly, MS Silverberg, K Lindblad, H Steinhart, Z Cohen, ... Nature genetics 29 (2), 223-228, 2001 | 998 | 2001 |
| PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial FJ Raal, EA Stein, R Dufour, T Turner, F Civeira, L Burgess, G Langslet, ... The Lancet 385 (9965), 331-340, 2015 | 976 | 2015 |
| Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study M Cuchel, EA Meagher, H du Toit Theron, DJ Blom, AD Marais, ... The Lancet 381 (9860), 40-46, 2013 | 910 | 2013 |
| Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus … HN Ginsberg, CJ Packard, MJ Chapman, J Borén, CA Aguilar-Salinas, ... European heart journal 42 (47), 4791-4806, 2021 | 893 | 2021 |
| Evinacumab for homozygous familial hypercholesterolemia FJ Raal, RS Rosenson, LF Reeskamp, GK Hovingh, JJP Kastelein, ... New England Journal of Medicine 383 (8), 711-720, 2020 | 808 | 2020 |
| Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on … EA Stein, D Gipe, J Bergeron, D Gaudet, R Weiss, R Dufour, R Wu, ... The Lancet 380 (9836), 29-36, 2012 | 716 | 2012 |
| Volanesorsen and triglyceride levels in familial chylomicronemia syndrome JL Witztum, D Gaudet, SD Freedman, VJ Alexander, A Digenio, ... New England Journal of Medicine 381 (6), 531-542, 2019 | 670 | 2019 |
| Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia C Gagné, D Gaudet, E Bruckert Circulation 105 (21), 2469-2475, 2002 | 659 | 2002 |
| Common variants in the NLRP3 region contribute to Crohn's disease susceptibility AC Villani, M Lemire, G Fortin, E Louis, MS Silverberg, C Collette, N Baba, ... Nature genetics 41 (1), 71-76, 2009 | 645 | 2009 |
| Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia D Gaudet, VJ Alexander, BF Baker, D Brisson, K Tremblay, W Singleton, ... New England Journal of Medicine 373 (5), 438-447, 2015 | 610 | 2015 |
| Targeting APOC3 in the familial chylomicronemia syndrome D Gaudet, D Brisson, K Tremblay, VJ Alexander, W Singleton, SG Hughes, ... New England Journal of Medicine 371 (23), 2200-2206, 2014 | 561 | 2014 |
| Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial D Gaudet, J Méthot, S Déry, D Brisson, C Essiembre, G Tremblay, ... Gene therapy 20 (4), 361-369, 2013 | 517 | 2013 |
| Small interfering RNA to reduce lipoprotein (a) in cardiovascular disease ML O’Donoghue, RS Rosenson, B Gencer, JAG López, NE Lepor, ... New England Journal of Medicine 387 (20), 1855-1864, 2022 | 492 | 2022 |
| Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance U Laufs, M Banach, GBJ Mancini, D Gaudet, LAT Bloedon, LR Sterling, ... Journal of the American Heart Association 8 (7), e011662, 2019 | 465 | 2019 |
| Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region JC Florez, N Burtt, PIW De Bakker, P Almgren, T Tuomi, J Holmkvist, ... Diabetes 53 (5), 1360-1368, 2004 | 389 | 2004 |
